Introduction
Bad is a member of the Bcl-2 homology domain 3 (BH3) family of proteins. It functions as a proapoptotic eector by counter-acting the anti-apoptotic functions of Bcl-xL (Yang et al., 1995) . Regulation of Bad is mediated by phosphorylation of two key serines proximal to the BH3 domain, which occurs in response to survival factors such as IL-3 and PDGF (Datta et al., 1997; Yang et al., 1995; Zha et al., 1996) . Phosphorylated Bad binds to the protein 14-3-3 and thus is prevented from displacing Bax from Bcl-xL (Zha et al., 1996) . The role of Bad in promoting apoptosis is well established; however, some data suggest that Bad may have growth-promoting properties as well. In transgenic mice that over-express Bad in the thymus, T-cells were more likely to be in S phase relative to control mice (Mok et al., 1999) . These Tcells expressed higher levels of activated Akt, a kinase that can act as a cell survival factor and that may play a role in cancer of the ovary, pancreas, and breast (Bellacosa et al., 1995; Cheng et al., 1996) . These opposing functions of Bad are reminiscent of similar activities seen with the transcription factors Jun and Myc which have both oncogenic and apoptotic potential (Bossy-Wetzel et al., 1997; Homan and Liebermann, 1998) . In this study, we examine the growth-promoting potential of Bad. We correlate enhanced growth with the association of Bad and a previously identi®ed partner, the protein 14-3-3, and identify serine 136 of Bad as a key element for this interaction.
Results
In CEF, Bad potentiates apoptosis in the absence of serum and promotes cell growth at high serum concentrations
The apoptosis-inducing activity of Bad in cultures of CEF was examined by phase contrast microscopy and a¯uorescence-based TUNEL assay (Figure 1 ). Serum withdrawal induced apoptosis in about 50% of the CEF transfected with wild-type Bad or with any one of the phosphorylation mutants within 6 h. CEF transfected with the vector control showed minimal cell death. Presence of serum prevented cell death in Badtransfected and control cultures. Under these conditions there was evidence for a growth-promoting eect of Bad: CEF transfected with wild-type Bad or the phosphorylation site mutant BadS112A produced vigorously growing agar colonies (Figure 2 ). However, CEF expressing the phosphorylation site mutant BadS136A showed no growth in nutrient agar, and vector-transfected CEF produced a low number of small, growth-arrested background colonies.
Induction of foci by Bad was evident at a calf serum concentration of 10%, but was not seen at a lower (3%) concentration (Figure 3 ). CEF transfected with Bad retained grossly normal morphology, but grew in multilayered fashion, which was a phenotype that was not seen with CEF transfected with vector control or BadS136A mutants. The saturation density of CEF transfected with Bad was 40% higher than that of CEF transfected with vector control and 50% higher than that of CEF transfected with the BadS136A mutant ( Figure 4) .
Cell cycle analysis of CEF transfected with vector, Bad, or Bad mutants grown in serum rich medium showed no signi®cant dierences in cell cycle pro®les, including the sub-G1 population (data not shown). These data suggest that the Bad protein does not increase proliferation rates in CEF in subcon¯uent cultures, but rather potentiates growth beyond saturation densities seen with control CEF transfected with vector or the BadS136A mutant (Figure 4) .
Wild-type Bad is constitutively phosphorylated at S112 and S136; in the mutated forms these sites cannot be phosphorylated ( Figure 5 ). The data show that Bad can induce anchorage-independent growth in CEF, and this growth-promoting eect is correlated with phosphorylation at serine 136 but not serine 112. The migration of Bad and the Bad mutants separated by SDS ± polyacrylamide gel electrophoresis cannot be fully explained by phosphorylation at the serine 112 and serine 136 sites. Recent reports indicate that Bad can be phosphorylated at serine 155, which may account for the altered mobility of the various Bad constructs (Datta et al., 2000; Tan et al., 2000; Virdee et al., 2000; Zhou et al., 2000) . Induction of anchorage-independent growth by Bad depends on binding to the protein 14-3-3
Phosphorylation reduces the apoptotic activity of Bad by interfering with the formation of Bcl-xL-Bad heterodimers and by facilitating the binding of Bad to the 14-3-3 protein (Zha et al., 1996) . Protein ± protein interactions of Bad in CEF were therefore tested by co-immunoprecipitations. An antibody directed against the AU1 epitope of the expressed Bad brought down co-precipitating bands at 34 ± 35 kDa ( Figure 6a ). These bands were seen in CEF expressing wild-type Bad or the mutant BadS112A but not in cells expressing the BadS136A mutation. Of the known binding partners of Bad, only the 14-3-3 protein migrates at this position (Zha et al., 1996) . Western blot of these immunoprecipitates probed with anti-14-3-3b antibody con®rmed that Bad and BadS112A, but not BadS136A and BadS112/136A, bind to 14-3-3 (Figure 6b ). The expression levels of Bad constructs and of 14-3-3 are roughly similar in each transfectant and do not account for the preferential binding of either Bad or BadS112A to 14-3-3.
Raf-1/MEK/Erk and PI-3-kinase pathways are not activated in Bad-transformed CEF Binding of Raf-1 to 14-3-3 stimulates Raf-1 kinase activity (Fu et al., 2000) . Other proteins which bind to 14-3-3 can activate or repress Raf-1 kinase activity through interfering with the interaction between Raf-1 and 14-3-3 (Aoki et al., 2000; Tzivion et al., 2000) . Therefore, we examined the possibility of an interference with Raf-1 signaling by Bad. We measured the levels of phosphorylated Erk-1/2 as a readout for the activation of Raf-1. CEF transfected with Bad constructs or with the empty vector expressed similar levels of Erk-1/2 and of phosphorylated Erk-1/2 (Figure 7) , suggesting that the 14-3-3/Bad interaction does not interfere with Raf-1 signaling.
The activity of Akt is increased in T-cells of Badtransgenic mice that over-express Bad in the thymus (Mok et al., 1999) . We examined Akt in Bad transformed CEF using phospho-speci®c antibodies that recognize activated Akt. In CEF, the levels of Akt phosphorylated at serine 473 were not correlated with over-expression of Bad or the BadS112A mutant (Figure 7) . Because the levels of phosphorylated Akt are the same in CEF expressing growth-promoting Bad and growth-neutral constructs, activation of Akt is probably not required for the growth-promoting eect of Bad.
Discussion
In high serum concentrations expression of Bad has a growth promoting eect on CEF. The cells reach higher saturation densities as compared to normal CEF, they acquire the ability of anchorage-independent growth, and high dilutions of the RCAS-Bad vector induce focal areas of increased cell density and moderate multilayering. This enhanced growth potential of Bad-expressing CEF is accompanied by mild changes in ®broblast morphology toward a more refractile phenotype, but these cells and the infectious RCAS-Bad retroviral vector are not oncogenic in newly hatched chickens (Maslyar, 2000, unpublished) . The enhanced growth induced by the Bad protein in CEF does not constitute full oncogenic transformation but, in conjunction with other growth promoting events, may be a contributing factor in carcinogenesis.
The switch from pro-apoptotic to pro-growth activity of Bad is controlled by serum and probably involves some serum dependent signals. Our data show that phosphorylation of Bad at serine 136 is a prerequisite for growth stimulation. This phosphoryl- Figure 4 Bad transfected CEF reach elevated saturation densities, whereas transfection with BadS136A does not increase growth Figure 5 Western blot of cell lysates with antibodies to the AU1 epitope and with phospho-serine speci®c antibodies show the expression and phosphorylation status of Bad constructs. Only CEF containing Bad phosphorylated at the serine 136 position produce agar colonies Oncogene Bad in chicken embryo fibroblasts DJ Maslyar et al ation is correlated with binding to protein 14-3-3, supporting the suggestion that 14-3-3 is a key factor in Bad-induced growth. Many proteins bind to 14-3-3, and 14-3-3 may serve as an integrator of information from multiple signaling cascades (Fu et al., 2000) . The association of Bad and 14-3-3 may modulate one or several of these cascades. We tested two of these potential targets, the Raf-1/MAP kinase pathway and PI-3-Kinase/Akt signaling, and found no eect of Bad on these activities. Other 14-3-3 interactions remain to be investigated. These include protein kinase C, the cdc25 phosphatase, and p53. Such tests are planned; they require additional information on the avian 14-3-3 isoforms that interact with these signaling molecules and will depend on the development of appropriate immunologic tools.
Accumulating data provide circumstantial evidence for involvement of Bad in cancer. Bad is overexpressed in the majority of the NCI anti-cancer drug screening cell lines, and phosphorylation of Bad is evident in many continuous cell lines (Kitada et al., 1998) . A recent clinical study of acute myelogenous leukemia found that the majority of these malignancies express Bad and that Bad is phosphorylated in 97% of these cases (Andree et al., 1999) . A related BH3 protein, Bak, is one of the most commonly upregulated genes in colon cancer cells as revealed by a recent screen for the adenomatous polyposis coli protein (Zhang et al., 1997) . Similar to Bad, Bak over-expression promotes apoptosis; the signi®cance of Bak over-expression in colon cancer remains to be determined (Chittenden et al., 1995; Zhang et al., 1997) .
Materials and methods

Plasmids and constructs
The RCAS vector, a replication-competent avian retrovirus, has been described (Hughes et al., 1987) . The human Bad cDNA was obtained from the American Type Culture Figure 6 Anchorage independent growth correlates with Bad interacting with 14-3-3. (a) Radiolabeled cells were lysed and immunoprecipitated with resin-bound AU1 antibody. The arrow marks dierentially co-immunoprecipitated bands. (b) Western blot of lysates probed with anti-14-3-3 demonstrates that these bands represent isoforms of 14-3-3. Pre-immunoprecipitated samples were probed with AU1 and 14-3-3 antibodies to show relative expression levels of Bad constructs and 14-3-3 (lower panels) Figure 7 Western blots of CEF transfected with the RCAS vector, Bad, and Bad mutants were probed with anti-phosphoErk and anti-Erk and show no change in expression levels. Parallel blots probed with anti-phospho-Akt and anti-Akt show that phosphorylated levels of Akt are slightly increased in Bad transfected CEF, however, total expression levels are unchanged throughout Collection as the I.M.A.G.E. consortium clone 1286754. This clone contains the sequence for amino acids 3 through 168. To produce an epitope-tagged Bad construct, the 5' primer, 5' -GCAGGATCCACCATGGACACCTACAGGTACATC -TTCCAGATCCCAGAGTTTGAGCCG-3', was generated to contain a BamHI site followed by an initiation codon and a sequence coding for the hexapeptide DTYRYI. This peptide is derived from the major capsid protein of the bovine papillomavirus type-1 and is recognized by the commercially available anti-AU1 antibody from Covance (Princeton, NJ, USA). The 3' primer contained the carboxyl-terminal six amino acids and stop codon of Bad as well as a HindIII site to facilitate cloning (5'-CCTAAGCTTGTGGAGCGAAG-GTCACTGGGAG-3'). The PCR product was isolated, subcloned into the adapter vector pBSFI, and the resulting S®I fragment was subcloned into RCAS-S® digested with S®I (Aoki et al., 1998) .
Site-directed mutagenesis of the phosphorylation sites of Bad substituted alanine for one or both of the critical phosphorylation sites, serine 112 and serine 136. It was conducted using the Quickchange kit by Stratagene (La Jolla, CA, USA). Serine 112 mutagenesis primers were as follows: 5'-GAGTCGCCACAGCGCCTACCCCGCGG-3' and 5'-CCGCGGGGTAGGCGCTGTGGCGACTC-3'; this mutant will be referred to as BadS112A; serine 136 mutagenesis primers were as follows: 5'-GCCGCTCGCGCGCGGCGCC-CCCCAAC-3' and 5'-GTTGGGGGGCGCCGCGCGCGA-GCGGC-3', this mutant will be referred to as BadS136A. From these single amino acid substitutions, the double mutant BadS112A/136A was generated.
Cell culture
Primary chicken embryo ®broblasts (CEF) were prepared from White Leghorn embryos obtained from SPAFAS (Norwich, CT, USA) as previously described (Vogt, 1969) . Transfection with RCAS constructs was performed with the dimethylsulfoxide-polybrene method (Kawai and Nishizawa, 1984) . Transfected CEF were maintained in cloning medium (F-10 medium supplemented with 10% donor calf serum, 4% chicken serum, 16 minimal essential medium vitamins, 2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin, 8 mg/ml folic acid, and 0.4% DMSO).
Agar colony assays and focus assays with virus stocks were performed as described (Bos et al., 1990) , with the concentration of donor calf serum increased to 10% in the focus assays. Cells were fed with nutrient agar every 2 ± 3 days. Agar colonies were counted and photographed at 3 weeks; foci were counted at 10 days after infection. Cells used for saturation density were grown under nutrient agar used for focus assays. Every 2 days, agar was removed from a subset of samples, and cells were trypsinized and counted until peak cell concentrations were obtained.
Apoptosis assays
CEF transfected with the empty RCAS vector or with RCAS-Bad constructs were passaged three times and then plated at 2610 5 cells per 35 mm dish. After overnight incubation in growth medium (F-10 medium supplemented with 6% iron-enriched calf serum, 2 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin), cells were changed to serum-free F-10 medium containing 1.6 mM Lglutamine, 80 units/ml penicillin, and 80 mg/ml streptomycin. Morphologic changes characteristic of apoptosis (membrane blebbing, cell shrinkage and nuclear fragmentation) were determined with phase-contrast optics. An average of 440 cells were scored per sample, and all assays were performed in duplicate. Data from phase-contrast microscopy were complemented at 0 and 6 h with assays for DNA fragmentation by TdT-mediated dUTP-digoxin nick end-labeling (TUNEL assay, Apoptag by Intergen, Milford, MA, USA). Controls were processed in parallel without withdrawal of serum.
Western blot analysis
Cells were harvested in a triple detergent lysis buer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecylsulfate, 1% Nonidet P-40, 0.5% sodium deoxycholate, 100 mg/ ml phenylmethylsulfonyl¯uoride, 2 mg/ml peptostatin A) and pre-cleared by centrifugation at 14 000 r.p.m. in a tabletop centrifuge at 48C for 10 min. Fifty mg of protein loaded per lane were separated by SDS ± polyacrylamide gel electrophoresis and subsequently were transferred to Immobilon P membranes (Millipore Corporation, Bedford, MA, USA). The membranes were probed with the following primary antibodies: anti-AU1 from Covance (Princeton, NJ, USA); anti-phospho-Bad112, anti-phospho-Bad136, anti-phospho-MAPK (E10 clone), anti-phospho-Akt, and anti-Akt from NEN Life Science Products (Boston, MA, USA); anti-14-3-3b and anti-Erk-2 from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Membranes were probed with secondary antibodies conjugated to horseradish peroxidase (anti-mouse-HRP and anti-rabbit-HRP from NEN, anti-goat-HRP from Pierce, Rockford, IL, USA) and were developed by enhanced chemiluminescence (Renaissance Plus, NEN Life Science Products, Boston, MA, USA). All Western blots were repeated to verify results.
Co-immunoprecipitation
CEF transfected with empty RCAS or RCAS-Bad constructs were plated at 3610 6 cells per 100 mm dish in cloning medium and were grown overnight. Cells were harvested in ice-cold PBS/5 mM EDTA (8.0) and were resuspended in coimmunoprecipitation buer (100 mM KCl, 50 mM Tris, pH 7.5, 0.5% Nonidet P-40, 100 mg/ml phenylmethylsulfonyl uoride, 2 mg/ml peptostatin A). After incubation for 10 min on ice, lysates were pre-cleared by centrifugation for 10 min at 14 000 r.p.m. Buer-equilibrated anti-AU1 resin (Covance, Princeton, NJ, USA) was added to the supernatant, and the samples were gently mixed at 48C for 1 h. The resin was collected by centrifugation, washed ®ve times with coimmunoprecipitation buer, and boiled in 16SDS loading buer prior to electrophoresis. Radiolabeled cells were prepared as above with the following changes: Four hours prior to harvesting, cells were incubated in cloning medium prepared from methionine free Dulbecco's modi®ed Eagle's medium containing chicken and calf serum which were dialyzed against PBS, and [ 35 S]methionine at 100 mCi per ml (NEN Life Science Products, Boston, MA, USA). Radiolabeled samples were separated by SDS ± polyacrylamide gel electrophoresis, ®xed in 30% methanol/10% glacial acetic acid, and saturated with autoradiography enhancer (Enhance, NEN Life Science Products, Boston, MA, USA) following the instructions of the manufacturer. Acrylamide gels were dried onto Whatman paper and were exposed to ®lm for 1 ± 7 days prior to developing.
